首页 | 本学科首页   官方微博 | 高级检索  
     


Belatacept‐Based Immunosuppression in De Novo Liver Transplant Recipients: 1‐Year Experience From a Phase II Randomized Study
Authors:G. B. Klintmalm  S. Feng  J. R. Lake  H. E. Vargas  T. Wekerle  S. Agnes  K. A. Brown  B. Nashan  L. Rostaing  S. Meadows‐Shropshire  M. Agarwal  M. B. Harler  J.‐C. García‐Valdecasas
Affiliation:1. Annette C. and Harold C. Simmons Transplant Institute, Baylor University Medical Center, , Dallas, TX;2. Division of Transplant Surgery, University of California, San Francisco, , San Francisco, CA;3. Liver Transplant Program, University of Minnesota, , Minneapolis, MN;4. Division of Hepatology, Mayo Clinic Arizona, , Phoenix, AZ;5. Division of Transplantation, Medical University of Vienna, , Vienna, Austria;6. Department of General and Transplant Surgery, Catholic University, Policlinico “A. Gemelli”, , Rome, Italy;7. Division of Gastroenterology, Henry Ford Health Systems, , Detroit, MI;8. Department of Hepatobiliary Surgery & Visceral Transplantation, University Medical Center Hamburg‐Eppendorf, , Hamburg, Germany;9. Department of Nephrology and Organ Transplantation, Toulouse University Hospital, , Toulouse, France;10. INSERM U1043, IFR‐BMT, CHU Purpan, , Toulouse, France;11. Bristol‐Myers Squibb, , Hopewell, NJ;12. Bristol‐Myers Squibb, , Princeton, NJ;13. Liver Transplant Unit, Hospital Clinic of Barcelona, , Barcelona, Spain
Abstract:
Keywords:Clinical research/practice  liver transplantation/hepatology  immunosuppressant, calcineurin inhibitor: tacrolimus, glomerular filtration rate (GFR)  immunosuppressant, fusion proteins and monoclonal antibodies: belatacept
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号